- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06561958
Estudio prospectivo, multicéntrico y no intervencionista para investigar la eficacia de REKOVELLE® para la estimulación ovárica en mujeres asiáticas en entornos del mundo real (PROFOUND)
Estudio prospectivo, multinacional y no intervencionista para investigar REKOVELLE para la estimulación ovárica: la eficacia, la seguridad y los patrones de uso para mujeres asiáticas en la práctica del mundo real
Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Busan, Corea del Sur, 47245
- Ferring Investigational Site
-
Seoul, Corea del Sur, 02586
- Maria Fertility Hospital
-
-
Busan
-
Busan, Busan, Corea del Sur, 49241
- Ferring Investigational Site
-
-
Daegu
-
Daegu, Daegu, Corea del Sur, 41910
- Ferring Investigational Site
-
-
Seongnam
-
Seongnam-si, Seongnam, Corea del Sur, 13496
- Ferring Investigational Site
-
-
-
-
-
Hiroshima, Japón, 7300035
- Ferring Investigational Site
-
Hokkaido, Japón, 0600003
- Ferring Investigational Site
-
Hyōgo, Japón, 6500021
- Ferring Investigational Site
-
Osaka, Japón, 5300011
- Ferring Investigational Site
-
Osaka, Japón, 5500015
- Ferring Investigational Site
-
Saitama, Japón, 3540035
- Ferring Investigational Site
-
-
Chiba
-
Chiba, Chiba, Japón, 2610023
- Ferring Investigational Site
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japón, 8120013
- Ferring Investigational Site
-
Kitakyushu, Fukuoka, Japón, 8070825
- Ferring Investigational Site
-
-
Gunma
-
Takasaki, Gunma, Japón, 3700841
- Ferring Investigational Site
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japón, 7320822
- Ferring Investigational Site
-
-
Japan
-
Bunkyō City, Japan, Japón, 1130033
- Ferring Investigational Site
-
-
Tokyo
-
Tokyo, Tokyo, Japón, 1600023
- Ferring Investigational Site
-
-
-
-
-
Bangkok, Tailandia, 10700
- Ferring Investigational Site
-
-
Muang
-
Phitsanulok, Muang, Tailandia, 65000
- Naresuan University Hospital
-
-
Ratchathewi
-
Bangkok, Ratchathewi, Tailandia, 10400
- Ramathibodi Hospital
-
-
-
-
-
Taichung, Taiwán, 406
- Ferring Investigational Site
-
Taipei, Taiwán, 100225
- Ferring Investigational Site
-
Taipei, Taiwán, 110
- Ferring Investigational Site
-
-
Tainan
-
Tainan, Tainan, Taiwán, 70403
- Ferring Investigational Site
-
Tainan, Tainan, Taiwán, 71004
- Ferring Investigational Site
-
-
Taoyuan
-
Taoyuan, Taoyuan, Taiwán, 333
- Ferring Investigational Site
-
-
-
-
Hanoi
-
Hanoi, Hanoi, Vietnam, 100000
- Ferring Investigational Site
-
-
Ho Chi Minh City
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
- Ferring Investigational Site
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam
- Ferring Investigational Site
-
-
Huế
-
Huế, Huế, Vietnam, 49000
- Ferring Investigational Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.
Descripción
Inclusion Criteria:
- Females aged 20 years or older at enrollment
- Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
- Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
- Participating in an interventional clinical trial in which any medication treatment is mandated
- Women with a contraindication for prescription of REKOVELLE treatment
- Oocyte donors
- Undergoing ovarian stimulation for fertility preservation
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
REKOVELLE
Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation. |
Individualised dosing regiment of REKOVELLE in routine clinical practice. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cumulative live birth rate
Periodo de tiempo: Up to 12 months
|
Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle. |
Up to 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The Luteinising hormone (LH) surge suppression protocol
Periodo de tiempo: Up to 22 days
|
Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol. |
Up to 22 days
|
|
Daily Dosage
Periodo de tiempo: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage. |
Up to 22 days
|
|
Stimulation Duration
Periodo de tiempo: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration. |
Up to 22 days
|
|
Total Dosage
Periodo de tiempo: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage. |
Up to 22 days
|
|
Trigger Protocol
Periodo de tiempo: Up to 22 days
|
Treatment pattern will be measured by analysing the trigger protocol. |
Up to 22 days
|
|
Luteal phase support protocol
Periodo de tiempo: Up to 22 days
|
Treatment pattern will be measured by analysing the luteal phase support protocol. |
Up to 22 days
|
|
Number of oocytes retrieved
Periodo de tiempo: Up to 22 days
|
Number of oocytes retrieved at oocyte retrieval |
Up to 22 days
|
|
Number of Metaphase II (MII) oocytes
Periodo de tiempo: Up to 22 days
|
Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI)) |
Up to 22 days
|
|
Number of embryos
Periodo de tiempo: Day 3 after oocyte retrieval
|
Number of embryos on Day 3 after oocyte retrieved |
Day 3 after oocyte retrieval
|
|
Number of Blastocysts
Periodo de tiempo: Day 5 after oocyte retrieval
|
Number of Blastocysts on Day 5 after oocyte retrieved |
Day 5 after oocyte retrieval
|
|
Number of embryos transferred
Periodo de tiempo: Up to 28 days
|
Embryos transferred in fresh and/or frozen transfer cycles |
Up to 28 days
|
|
Number of blastocysts transferred
Periodo de tiempo: Up to 28 days
|
Blastocysts transferred in fresh and/or frozen transfer cycles |
Up to 28 days
|
|
Implantation rate
Periodo de tiempo: Up to 28 days
|
Number of gestational sacs, embryos or blastocysts transferred |
Up to 28 days
|
|
Positive human chorionic gonadotropin (hCG) rate
Periodo de tiempo: 11 to 15 days after transfer
|
Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer |
11 to 15 days after transfer
|
|
Clinical Pregnancy rate
Periodo de tiempo: 4 to 5 weeks after transfer
|
Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer) |
4 to 5 weeks after transfer
|
|
Vital Pregnancy
Periodo de tiempo: 4 to 5 weeks after transfer
|
Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer) |
4 to 5 weeks after transfer
|
|
Ongoing pregnancy rate
Periodo de tiempo: 9 to 11 weeks after transfer
|
Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer) |
9 to 11 weeks after transfer
|
|
Time to pregnancy
Periodo de tiempo: 4 to 5 weeks after transfer
|
Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy |
4 to 5 weeks after transfer
|
|
Live birth rate
Periodo de tiempo: More than 20 weeks after transfer
|
Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle. |
More than 20 weeks after transfer
|
|
Multiple pregnancy rate
Periodo de tiempo: 4 to 5 weeks after transfer
|
More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer |
4 to 5 weeks after transfer
|
|
Spontaneous abortion rate
Periodo de tiempo: Up to 10-11 weeks after transfer
|
Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound |
Up to 10-11 weeks after transfer
|
|
Ectopic pregnancy rate
Periodo de tiempo: Up to 10-11 weeks after transfer
|
Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery. |
Up to 10-11 weeks after transfer
|
|
Estradiol Hormone levels
Periodo de tiempo: Up to 20 days
|
Estradiol hormone levels before stimulation and at the end of stimulation day |
Up to 20 days
|
|
Progesterone Hormone levels
Periodo de tiempo: Up to 20 days
|
Progesterone hormone levels before stimulation and at the end of stimulation day |
Up to 20 days
|
|
Cycle cancellation rate and the reason for cycle cancellation
Periodo de tiempo: Up to 28 days
|
Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason) |
Up to 28 days
|
|
Transfer cancellation rate and the reason for transfer cancellation
Periodo de tiempo: Up to 28 days
|
Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation). |
Up to 28 days
|
|
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Periodo de tiempo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Frequency and severity of ADRs and SAEs as defined by the investigator |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
|
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Periodo de tiempo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
|
Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer) |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
|
|
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Periodo de tiempo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Number of subjects with mild / moderate / severe OHSS, defined by the investigator |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Global Clinical Compliance, Ferring Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 000430
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .